US5800815A
(en)
|
1903-05-05 |
1998-09-01 |
Cytel Corporation |
Antibodies to P-selectin and their uses
|
US6309639B1
(en)
|
1991-02-05 |
2001-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
|
US5213796A
(en)
|
1991-05-06 |
1993-05-25 |
Dana Farber Cancer Institute |
Assay for polyomavirus in humans and uses thereof
|
US5726014A
(en)
|
1991-06-27 |
1998-03-10 |
Genelabs Technologies, Inc. |
Screening assay for the detection of DNA-binding molecules
|
US5578444A
(en)
|
1991-06-27 |
1996-11-26 |
Genelabs Technologies, Inc. |
Sequence-directed DNA-binding molecules compositions and methods
|
DK0642356T3
(en)
|
1992-05-05 |
2003-08-04 |
Aeres Biomedical Ltd |
Antibodies to P-selectin and their uses
|
US7910624B1
(en)
|
1995-03-03 |
2011-03-22 |
The Trustees Of Boston University |
Compositions for the treatment of blood disorders
|
WO1995011699A1
(en)
|
1993-10-29 |
1995-05-04 |
The Trustees Of Boston University |
Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
US6503717B2
(en)
|
1999-12-06 |
2003-01-07 |
Sangamo Biosciences, Inc. |
Methods of using randomized libraries of zinc finger proteins for the identification of gene function
|
US6599692B1
(en)
|
1999-09-14 |
2003-07-29 |
Sangamo Bioscience, Inc. |
Functional genomics using zinc finger proteins
|
US7070934B2
(en)
|
1999-01-12 |
2006-07-04 |
Sangamo Biosciences, Inc. |
Ligand-controlled regulation of endogenous gene expression
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
US6780590B2
(en)
|
1999-09-14 |
2004-08-24 |
Sangamo Biosciences, Inc. |
Gene identification
|
US20020164575A1
(en)
|
1999-09-14 |
2002-11-07 |
Sangamo Biosciences, Inc., A Delaware Corporation |
Gene identification
|
IT1320168B1
(en)
|
2000-03-13 |
2003-11-18 |
Univ Ferrara |
SYNTHETIC OLIGONUCLEOTIDES THAT CAN INDUCE THE ERYTHROID DIFFERENTIATION.
|
WO2001085765A2
(en)
|
2000-05-12 |
2001-11-15 |
Merck Patent Gmbh |
Identification of mfq-110, a human c2h2-type zinc finger protein
|
US20050054836A1
(en)
|
2000-11-09 |
2005-03-10 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
AU2002219992A1
(en)
|
2000-12-01 |
2002-06-11 |
Sangamo Biosciences, Inc. |
Targeted regulation of gene expression
|
AU2002309583A1
(en)
|
2001-04-18 |
2002-11-05 |
Protein Desing Labs, Inc. |
Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
|
WO2003027247A2
(en)
|
2001-09-24 |
2003-04-03 |
Sangamo Biosciences, Inc. |
Modulation of stem cells using zinc finger proteins
|
EP2806025B1
(en)
|
2002-09-05 |
2019-04-03 |
California Institute of Technology |
Use of zinc finger nucleases to stimulate gene targeting
|
WO2004054512A2
(en)
|
2002-12-13 |
2004-07-01 |
Genetix Pharmaceuticals, Inc. |
Therapeutic retroviral vectors for gene therapy
|
US20050025753A1
(en)
|
2003-04-30 |
2005-02-03 |
Wei Han |
Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
|
WO2005014791A2
(en)
|
2003-08-08 |
2005-02-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
US8409861B2
(en)
|
2003-08-08 |
2013-04-02 |
Sangamo Biosciences, Inc. |
Targeted deletion of cellular DNA sequences
|
US7888121B2
(en)
|
2003-08-08 |
2011-02-15 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
JP5059411B2
(en)
|
2003-12-19 |
2012-10-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
Cell transfection formulations of short interfering RNA, related compositions and methods of making and uses
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
US7972854B2
(en)
|
2004-02-05 |
2011-07-05 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted cleavage and recombination
|
DK1737891T3
(en)
|
2004-04-13 |
2013-03-25 |
Hoffmann La Roche |
ANTI-P-selectin ANTIBODIES
|
WO2007014181A2
(en)
|
2005-07-25 |
2007-02-01 |
Johns Hopkins University |
Site-specific modification of the human genome using custom-designed zinc finger nucleases
|
LT2662091T
(en)
|
2006-12-01 |
2018-12-10 |
Novartis Ag |
Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
|
US8945565B2
(en)
|
2006-12-01 |
2015-02-03 |
Selexys Pharmaceuticals Corporation |
Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
|
US20110212096A1
(en)
|
2006-12-01 |
2011-09-01 |
Scott Rollins |
Anti-p-selectin antibodies and methods of their use and identification
|
GB0713183D0
(en)
|
2007-07-06 |
2007-08-15 |
King S College London |
Method
|
ES2738980T3
(en)
|
2008-09-15 |
2020-01-28 |
Childrens Medical Ct Corp |
Modulation of BCL11A for the treatment of hemoglobinopathies
|
PE20100362A1
(en)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
|
SG10201407996PA
(en)
|
2009-12-23 |
2015-01-29 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
WO2011103215A1
(en)
|
2010-02-16 |
2011-08-25 |
Mount Sinai School Of Medicine |
Embedded chimeric peptide nucleic acids and use thereof
|
WO2012075027A1
(en)
|
2010-11-29 |
2012-06-07 |
Mount Sinai School Of Medicine |
Embedded chimeric peptide nucleic acids for generation of induced pluripotent stem cells
|
MX2013000164A
(en)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Liposomes with lipids having an advantageous pka- value for rna delivery.
|
US20140127814A1
(en)
|
2010-08-10 |
2014-05-08 |
Srinivasan Chandrasegaran |
Generation and use of pluripotent stem cells
|
BR112013004865A2
(en)
|
2010-08-31 |
2016-06-07 |
Novartis Ag |
lipids suitable for liposomal delivery of rna protein coders
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
WO2012112232A1
(en)
|
2011-02-18 |
2012-08-23 |
Academia Sinica |
METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE
|
DE202011050611U1
(en)
|
2011-07-01 |
2012-10-09 |
Makita Corporation |
Arrangement for providing a fuel-air mixture for an internal combustion engine
|
RU2014104090A
(en)
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
LIPOSOMES WITH AN EFFECTIVE N: P RATIO FOR DELIVERY OF PHK MOLECULES
|
WO2013019745A1
(en)
|
2011-07-29 |
2013-02-07 |
Georgia Health Sciences University |
Methods and compositions for genetically modifiying cells
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
WO2013059343A1
(en)
|
2011-10-17 |
2013-04-25 |
Massachusetts Institute Of Technology |
Intracellular delivery
|
US9394547B2
(en)
|
2012-01-03 |
2016-07-19 |
City University Of Hong Kong |
Method and apparatus for delivery of molecules to cells
|
US20130178421A1
(en)
|
2012-01-06 |
2013-07-11 |
Alcon Research, Ltd. |
Interfering rna delivery system and uses thereof
|
BR112014018524B1
(en)
|
2012-01-27 |
2023-03-28 |
Universite De Montreal |
PYRIMID [4,5-B]INDOL DERIVATIVES, THEIR USES, PHARMACEUTICAL COMPOSITION, AND IN VIVO OR EX VIVO METHOD TO INCREASE STEM AND/OR PROGENITOR CELLS
|
KR101833589B1
(en)
|
2012-02-24 |
2018-03-02 |
프레드 헛친슨 켄서 리서치 센터 |
Compositions and methods for the treatment of hemoglobinopathies
|
DK2839013T3
(en)
|
2012-04-18 |
2020-09-14 |
Univ Leland Stanford Junior |
NON-DISRUPTIVE-GEN-TARGETING
|
DE202013012242U1
(en)
|
2012-05-25 |
2016-02-02 |
Emmanuelle Charpentier |
Compositions for RNA-directed modification of a target DNA and for RNA-driven modulation of transcription
|
ES2962571T3
(en)
|
2012-05-25 |
2024-03-19 |
Cellectis |
Methods to modify allogeneic and immunosuppression-resistant T cells for immunotherapy
|
US20150017136A1
(en)
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
RU2014153918A
(en)
|
2012-06-12 |
2016-07-27 |
Дженентек, Инк. |
METHODS AND COMPOSITIONS FOR OBTAINING CONDITIONALLY KO-KOLLUTE ALLEYS
|
JP6329537B2
(en)
|
2012-07-11 |
2018-05-23 |
サンガモ セラピューティクス, インコーポレイテッド |
Methods and compositions for delivery of biological agents
|
CN105188767A
(en)
|
2012-07-25 |
2015-12-23 |
布罗德研究所有限公司 |
Inducible DNA binding proteins and genome perturbation tools and applications thereof
|
KR102218562B1
(en)
|
2012-08-29 |
2021-02-19 |
상가모 테라퓨틱스, 인코포레이티드 |
Methods and compositions for treatment of a genetic condition
|
KR102141259B1
(en)
|
2012-09-04 |
2020-08-05 |
셀렉티스 |
Multi-chain chimeric antigen receptor and uses thereof
|
DE202013012597U1
(en)
|
2012-10-23 |
2017-11-21 |
Toolgen, Inc. |
A composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and a Cas protein-encoding nucleic acid or Cas protein, and their use
|
CN109554350B
(en)
|
2012-11-27 |
2022-09-23 |
儿童医疗中心有限公司 |
Targeting BCL11A distal regulatory elements for fetal hemoglobin re-induction
|
PL3138910T3
(en)
|
2012-12-06 |
2018-01-31 |
Sigma Aldrich Co Llc |
Crispr-based genome modification and regulation
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
JP6552965B2
(en)
|
2012-12-12 |
2019-07-31 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
|
PL2931898T3
(en)
|
2012-12-12 |
2016-09-30 |
Le Cong |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
MX2015007549A
(en)
|
2012-12-12 |
2017-01-20 |
Broad Inst Inc |
Engineering of systems, methods and optimized guide compositions for sequence manipulation.
|
US20140186843A1
(en)
|
2012-12-12 |
2014-07-03 |
Massachusetts Institute Of Technology |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
US20140189896A1
(en)
|
2012-12-12 |
2014-07-03 |
Feng Zhang |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
WO2014099744A1
(en)
|
2012-12-17 |
2014-06-26 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
EP2958996B1
(en)
|
2013-02-25 |
2019-10-16 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
WO2014134412A1
(en)
|
2013-03-01 |
2014-09-04 |
Regents Of The University Of Minnesota |
Talen-based gene correction
|
EA030650B1
(en)
|
2013-03-08 |
2018-09-28 |
Новартис Аг |
Lipids and lipid compositions for the delivery of active agents
|
US10612043B2
(en)
|
2013-03-09 |
2020-04-07 |
Agilent Technologies, Inc. |
Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events
|
WO2014150624A1
(en)
|
2013-03-14 |
2014-09-25 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
US20140273230A1
(en)
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
US11332719B2
(en)
|
2013-03-15 |
2022-05-17 |
The Broad Institute, Inc. |
Recombinant virus and preparations thereof
|
KR102210319B1
(en)
|
2013-03-15 |
2021-02-01 |
더 제너럴 하스피탈 코포레이션 |
Rna-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
WO2014150256A1
(en)
|
2013-03-15 |
2014-09-25 |
Global Blood Therapeutics, Inc. |
Compositions and methods for the modulation of hemoglobin (s)
|
PT2970948T
(en)
|
2013-03-15 |
2019-03-20 |
Glaxosmithkline Biologicals Sa |
Rna purification methods
|
CA2908253C
(en)
|
2013-04-04 |
2024-01-09 |
Trustees Of Dartmouth College |
Compositions and methods for in vivo excision of hiv-1 proviral dna
|
US20150056629A1
(en)
|
2013-04-14 |
2015-02-26 |
Katriona Guthrie-Honea |
Compositions, systems, and methods for detecting a DNA sequence
|
US20160186208A1
(en)
|
2013-04-16 |
2016-06-30 |
Whitehead Institute For Biomedical Research |
Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
|
EP2997141B1
(en)
|
2013-05-13 |
2022-10-12 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
EP2997133B1
(en)
|
2013-05-13 |
2023-08-23 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
CN105683376A
(en)
|
2013-05-15 |
2016-06-15 |
桑格摩生物科学股份有限公司 |
Methods and compositions for treatment of a genetic condition
|
CA2907694A1
(en)
|
2013-05-24 |
2014-11-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
|
JP6670743B2
(en)
|
2013-05-29 |
2020-03-25 |
セレクティスCellectis |
Novel compact CAS9 scaffold in type II CRISPR system
|
ES2645393T3
(en)
|
2013-05-29 |
2017-12-05 |
Cellectis |
T lymphocyte manipulation methods for immunotherapy using the RNA-guided Cas nuclease system
|
WO2014197568A2
(en)
|
2013-06-04 |
2014-12-11 |
President And Fellows Of Harvard College |
Rna-guideded transcriptional regulation
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
EP3539573B1
(en)
*
|
2013-06-05 |
2024-02-14 |
Duke University |
Rna-guided gene editing and gene regulation
|
EP3008192B1
(en)
|
2013-06-11 |
2019-07-17 |
Takara Bio USA, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
US20150315252A1
(en)
|
2013-06-11 |
2015-11-05 |
Clontech Laboratories, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
RU2716421C2
(en)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Delivery, use and use in therapy of crispr-cas systems and compositions for targeted action on disorders and diseases using viral components
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
EP3011032B1
(en)
|
2013-06-17 |
2019-10-16 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
EP3011035B1
(en)
|
2013-06-17 |
2020-05-13 |
The Broad Institute, Inc. |
Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
KR20160034901A
(en)
|
2013-06-17 |
2016-03-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
BR112015031608A2
(en)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
APPLICATION AND USE OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGETING AND THERAPY
|
CN104239331B
(en)
|
2013-06-19 |
2018-10-09 |
阿里巴巴集团控股有限公司 |
A kind of method and apparatus for realizing comment search engine sequence
|
JP2016528890A
(en)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Therapeutic use of genome editing using the CRISPR / Cas system
|
SG10201913015XA
(en)
|
2013-07-10 |
2020-02-27 |
Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
PL3019619T3
(en)
|
2013-07-11 |
2022-01-10 |
Modernatx, Inc. |
Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
|
WO2015021426A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
SG10201801188XA
(en)
|
2013-08-16 |
2018-03-28 |
Massachusetts Inst Technology |
Selective delivery of material to cells
|
EP3611268A1
(en)
|
2013-08-22 |
2020-02-19 |
E. I. du Pont de Nemours and Company |
Plant genome modification using guide rna/cas endonuclease systems and methods of use
|
GB201315321D0
(en)
|
2013-08-28 |
2013-10-09 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Transduction Buffer
|
EP3041498B1
(en)
|
2013-09-05 |
2022-02-16 |
Massachusetts Institute of Technology |
Tuning microbial populations with programmable nucleases
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
DE202014010413U1
(en)
|
2013-09-18 |
2015-12-08 |
Kymab Limited |
Cells and organisms
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
US20160237455A1
(en)
|
2013-09-27 |
2016-08-18 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
JP5774657B2
(en)
|
2013-10-04 |
2015-09-09 |
国立大学法人京都大学 |
Method for genetic modification of mammals using electroporation
|
WO2015052231A2
(en)
|
2013-10-08 |
2015-04-16 |
Technical University Of Denmark |
Multiplex editing system
|
WO2015054507A1
(en)
|
2013-10-10 |
2015-04-16 |
Pronutria, Inc. |
Nutritive polypeptide production systems, and methods of manufacture and use thereof
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
US9850497B2
(en)
|
2013-11-04 |
2017-12-26 |
Regents Of The University Of Minnesota |
Gene targeting methods and tools
|
DK3066201T3
(en)
|
2013-11-07 |
2018-06-06 |
Editas Medicine Inc |
CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
|
SI3068881T1
(en)
|
2013-11-13 |
2019-05-31 |
Children's Medical Center Corporation |
Nuclease-mediated regulation of gene expression
|
AU2014350051A1
(en)
|
2013-11-18 |
2016-07-07 |
Crispr Therapeutics Ag |
CRISPR-Cas system materials and methods
|
WO2015075195A1
(en)
|
2013-11-22 |
2015-05-28 |
Cellectis |
Method of engineering chemotherapy drug resistant t-cells for immunotherapy
|
JP2016538001A
(en)
|
2013-11-28 |
2016-12-08 |
ホライズン・ジェノミクス・ゲーエムベーハー |
Somatic haploid human cell line
|
EP3079726B1
(en)
|
2013-12-12 |
2018-12-05 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
EP3080266B1
(en)
|
2013-12-12 |
2021-02-03 |
The Regents of The University of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
SG10201804974RA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
BR112016013201B1
(en)
|
2013-12-12 |
2023-01-31 |
The Broad Institute, Inc. |
USE OF A COMPOSITION COMPRISING A CRISPR-CAS SYSTEM IN THE TREATMENT OF A GENETIC OCULAR DISEASE
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
KR20160097327A
(en)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
SG10201804975PA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
|
US20150191744A1
(en)
|
2013-12-17 |
2015-07-09 |
University Of Massachusetts |
Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
|
WO2015095346A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
US10059655B2
(en)
|
2013-12-19 |
2018-08-28 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
EP3083958B1
(en)
|
2013-12-19 |
2019-04-17 |
Amyris, Inc. |
Methods for genomic integration
|
KR20160102056A
(en)
|
2013-12-26 |
2016-08-26 |
더 제너럴 하스피탈 코포레이션 |
Multiplex guide rnas
|
US9963689B2
(en)
|
2013-12-31 |
2018-05-08 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
WO2015105928A1
(en)
|
2014-01-08 |
2015-07-16 |
President And Fellows Of Harvard College |
Rna-guided gene drives
|
WO2015112896A2
(en)
|
2014-01-24 |
2015-07-30 |
North Carolina State University |
Methods and compositions for sequences guiding cas9 targeting
|
PL3102673T3
(en)
|
2014-02-03 |
2020-11-02 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
US10287590B2
(en)
|
2014-02-12 |
2019-05-14 |
Dna2.0, Inc. |
Methods for generating libraries with co-varying regions of polynuleotides for genome modification
|
CN113265394A
(en)
|
2014-02-13 |
2021-08-17 |
宝生物工程(美国) 有限公司 |
Methods of depleting target molecules from an initial collection of nucleic acids, and compositions and kits for practicing same
|
JP2017506893A
(en)
|
2014-02-18 |
2017-03-16 |
デューク ユニバーシティ |
Viral replication inactivating composition and method for producing and using the same
|
CA3194412A1
(en)
|
2014-02-27 |
2015-09-03 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
EP3126498A4
(en)
|
2014-03-20 |
2017-08-23 |
Université Laval |
Crispr-based methods and products for increasing frataxin levels and uses thereof
|
US10451633B2
(en)
|
2014-03-24 |
2019-10-22 |
IMMCO Diagnostics, Inc. |
Anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
|
WO2015148670A1
(en)
|
2014-03-25 |
2015-10-01 |
Editas Medicine Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
WO2015148860A1
(en)
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating beta-thalassemia
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
JP6695795B2
(en)
|
2014-03-31 |
2020-05-20 |
株式会社サイエンス・ラスター |
Hematopoietic cell growth peptide and uses thereof
|
EP4123024A1
(en)
|
2014-04-01 |
2023-01-25 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
WO2015153791A1
(en)
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
|
US20170029850A1
(en)
|
2014-04-02 |
2017-02-02 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
EP3126503A1
(en)
|
2014-04-03 |
2017-02-08 |
Massachusetts Institute Of Technology |
Methods and compositions for the production of guide rna
|
EP3556858A3
(en)
|
2014-04-09 |
2020-01-22 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
HUE051354T2
(en)
|
2014-04-14 |
2021-03-01 |
Nemesis Bioscience Ltd |
Therapeutic
|
JP2017513485A
(en)
|
2014-04-18 |
2017-06-01 |
エディタス・メディシン,インコーポレイテッド |
CRISPR-CAS related methods, compositions and components for cancer immunotherapy
|
AU2015249381B2
(en)
|
2014-04-25 |
2020-04-30 |
Children's Medical Center Corporation |
Compositions and methods to treating hemoglobinopathies
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
EP3140403A4
(en)
|
2014-05-09 |
2017-12-20 |
Université Laval |
Prevention and treatment of alzheimer's disease by genome editing using the crispr/cas system
|
US20170088819A1
(en)
|
2014-05-16 |
2017-03-30 |
Vrije Universiteit Brussel |
Genetic correction of myotonic dystrophy type 1
|
WO2015179540A1
(en)
|
2014-05-20 |
2015-11-26 |
Regents Of The University Of Minnesota |
Method for editing a genetic sequence
|
WO2015188056A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
LT3152312T
(en)
|
2014-06-06 |
2020-04-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for modifying a targeted locus
|
CA2951707A1
(en)
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
WO2015191911A2
(en)
|
2014-06-12 |
2015-12-17 |
Clontech Laboratories, Inc. |
Protein enriched microvesicles and methods of making and using the same
|
HUE049405T2
(en)
|
2014-06-23 |
2020-09-28 |
Regeneron Pharma |
Nuclease-mediated dna assembly
|
WO2015200555A2
(en)
|
2014-06-25 |
2015-12-30 |
Caribou Biosciences, Inc. |
Rna modification to engineer cas9 activity
|
US20150376586A1
(en)
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
HUE041584T2
(en)
|
2014-06-26 |
2019-05-28 |
Regeneron Pharma |
Methods and compositions for targeted genetic modifications and methods of use
|
US10017770B2
(en)
|
2014-07-03 |
2018-07-10 |
Ut-Battelle, Llc |
TNT cloning system
|
CA2954686A1
(en)
|
2014-07-11 |
2016-01-14 |
Pioneer Hi-Bred International, Inc. |
Agronomic trait modification using guide rna/cas endonuclease systems and methods of use
|
EP3169776A4
(en)
|
2014-07-14 |
2018-07-04 |
The Regents of The University of California |
Crispr/cas transcriptional modulation
|
US10975406B2
(en)
|
2014-07-18 |
2021-04-13 |
Massachusetts Institute Of Technology |
Directed endonucleases for repeatable nucleic acid cleavage
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
AU2015311681B2
(en)
|
2014-09-04 |
2021-09-23 |
Memorial Sloan-Kettering Cancer Center |
Globin gene therapy for treating hemoglobinopathies
|
WO2016044416A1
(en)
|
2014-09-16 |
2016-03-24 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
CA2963693A1
(en)
|
2014-10-10 |
2016-04-14 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
EP3215617B1
(en)
|
2014-11-07 |
2024-05-08 |
Editas Medicine, Inc. |
Systems for improving crispr/cas-mediated genome-editing
|
EP3230452A1
(en)
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
EP3702456A1
(en)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
EP3237017A4
(en)
|
2014-12-24 |
2018-08-01 |
Dana-Farber Cancer Institute, Inc. |
Systems and methods for genome modification and regulation
|
CN107429263A
(en)
|
2015-01-15 |
2017-12-01 |
斯坦福大学托管董事会 |
The method of controlling gene group editor
|
WO2016118726A2
(en)
|
2015-01-21 |
2016-07-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for identification of highly specific nucleases
|
US10350245B2
(en)
|
2015-01-21 |
2019-07-16 |
Fred Hutchinson Cancer Research Center |
Point-of-care and/or portable platform for gene therapy
|
WO2016118715A1
(en)
|
2015-01-21 |
2016-07-28 |
Cornell University |
Viral vectors for prophylaxis and therapy of hemoglobinopathies
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
WO2016135557A2
(en)
*
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US20180271891A1
(en)
|
2015-03-11 |
2018-09-27 |
The Broad Institute Inc. |
Selective treatment of prmt5 dependent cancer
|
WO2016154596A1
(en)
|
2015-03-25 |
2016-09-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
EP3274453B1
(en)
|
2015-03-26 |
2021-01-27 |
Editas Medicine, Inc. |
Crispr/cas-mediated gene conversion
|
CA2978659C
(en)
|
2015-03-31 |
2023-05-16 |
Glycotope Gmbh |
Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters
|
CN107787367B
(en)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
Chemically modified guide RNAs for CRISPR/CAS mediated gene regulation
|
WO2016182917A1
(en)
|
2015-05-08 |
2016-11-17 |
Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
CA2984013A1
(en)
|
2015-05-12 |
2016-11-17 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
WO2016201272A1
(en)
|
2015-06-12 |
2016-12-15 |
King Abdulaziz City For Science And Technology |
Method of diagnosing patients with conditions caused by mendelian mutations
|
EP3310932B1
(en)
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
EP3356520B1
(en)
|
2015-10-02 |
2022-03-23 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
US20180273609A1
(en)
|
2015-11-04 |
2018-09-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
BR112018013065A2
(en)
|
2015-12-28 |
2018-12-11 |
Intellia Therapeutics Inc |
compositions and methods for the treatment of hemoglobinopathies
|
MX2018011114A
(en)
*
|
2016-03-14 |
2019-02-20 |
Editas Medicine Inc |
Crispr/cas-related methods and compositions for treating beta hemoglobinopathies.
|
JP6974349B2
(en)
|
2016-04-18 |
2021-12-01 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
Materials and methods for the treatment of hemoglobin abnormalities
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017218948A2
(en)
|
2016-06-17 |
2017-12-21 |
Fred Hutchinson Cancer Research Center |
Strategies to assess and/or produce cell populations with predictive engraftment potential
|
US20190316154A1
(en)
|
2016-07-07 |
2019-10-17 |
St. Jude Children's Research Hospital |
Erythroid-specific promoter and method of use thereof
|
AU2017301609A1
(en)
|
2016-07-25 |
2019-02-21 |
Bluebird Bio, Inc. |
BCL11A homing endonuclease variants, compositions, and methods of use
|
AU2017312132A1
(en)
|
2016-08-19 |
2019-03-21 |
Bluebird Bio, Inc. |
Genome editing enhancers
|
CN110325635B
(en)
|
2016-08-24 |
2023-12-26 |
桑格摩生物治疗股份有限公司 |
Regulation of gene expression using engineered nucleases
|
KR102455249B1
(en)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
Engineered target specific nuclease
|
EP3519577A1
(en)
|
2016-09-28 |
2019-08-07 |
Novartis AG |
Porous membrane-based macromolecule delivery system
|